COVID-19 pandemic
India approves the phase II and III trials of the country's first domestic MRNA-based HGC019 vaccine made by Gennova Biopharmaceuticals after the early-stage study found that the vaccine is safe and effective.
Sources: Al Jazeera
Changes
- India approves the phase II and III trial of the country's first homegrown MRNA-based HGC019 vaccine made by Gennova Biopharmaceuticals after the early-stage study found the shot is safe and effective.
- India approves the phase II and III trials of the country's first domestic MRNA-based HGC019 vaccine made by Gennova Biopharmaceuticals after the early-stage study found that the vaccine is safe and effective.